Human Immunodeficiency Virus and Pulmonary Arterial Hypertension

Mirrakhimov, Aibek E.; Ali, Alaa M.; Barbaryan, Aram; Prueksaritanond, Suartcha

doi:10.1155/2013/903454

Cited by 11 publications

(13 citation statements)

References 83 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pulmonary arterial hypertension (PAH) is a life‐threatening complication in patients with human immunodeficiency virus (HIV) infection and is observed in approximately 0.5% of these patients . In patients with PAH, prostacyclin concentrations in the lung are markedly decreased .…”

Section: Introductionmentioning

confidence: 99%

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

Kaufmann

Niglis

Bruderer

et al. 2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

AIMSThis study investigated the effect of a fixed dose combination of lopinavir/ritonavir on the pharmacokinetics (PK) of selexipag and its active metabolite ACT-333679. METHODSThis was an open label, randomized, single centre, two way, crossover study. Twenty healthy male subjects were treated with a single dose of 400 μg selexipag alone and in combination with multiple doses of lopinavir/ritonavir (400/100 mg) twice daily. RESULTSThe results showed that lopinavir/ritonavir approximately doubled the exposure to selexipag. The area under the plasma concentration-time curve from time zero to infinity (AUC(0,1) and the maximum plasma concentration (C max ) of selexipag were 2.2-and 2.1-fold higher, respectively, than under selexipag alone, with a 90% confidence interval (CI) of the geometric mean ratio (GMR) of 1.9, 2.7 and 1.7, 2.6, respectively. For ACT-333679, the clinically more relevant component of selexipag, systemic exposure was increased by 8% (GMR of AUC(0,1) 1.1, 90% CI 0.9, 1.3), when lopinavir/ritonavir was co-administered with selexipag. The most frequently reported adverse event (AE) was headache. A single dose of selexipag, administered either alone or together with multiple doses of lopinavir/ritonavir, was safe and well tolerated. CONCLUSIONSLopinavir/ritonavir does not affect the PK parameters of selexipag and ACT-333679 to a clinically relevant extent. Therefore, adaptation of the selexipag dose is not required when co-administered with inhibitors of the organic anion-transporting polypeptide (OATP) 1B1/ 1B3, P-glycoprotein (P-gp) and/or CYP3A4.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

Kaufmann

Niglis

Bruderer

et al. 2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…También se ha descrito mayor prevalencia de HLA-DR6 y HLA-DR52 en pacientes con HTP asociada a VIH. 8,9 La clínica es inespecífica. El síntoma principal es la disnea, generalmente, progresiva.…”

Section: Figura 2 A: Ecocardiograma Inicial Se Observa Una Grave DIunclassified

“…La fisiopatología es compleja y probablemente multifactorial; en ella, podrían contribuir la inflamación sistémica por VIH y la coinfección con otros microorganismos. [6][7][8][9] En el manejo de esta patología, son importantes tanto la terapia específica de la HTP como el TARV y el de las infecciones concomitantes. Esta conducta, adoptada en nuestro paciente, demostró buenos resultados.…”

Section: Figura 2 A: Ecocardiograma Inicial Se Observa Una Grave DIunclassified

Hipertensión pulmonar asociada al virus de la inmunodeficiencia humana en pediatría: tratamiento con sildenafil. A propósito de un caso

Stepffer

Gaynor

López

et al. 2018

Arch Argent Pediatr

View full text Add to dashboard Cite

Presentación de casos clínicos RESUMENLa hipertensión pulmonar asociada a la infección por virus de inmunodeficiencia humana es una enfermedad sumamente infrecuente en pediatría, por lo que requiere alta sospecha clínica para llegar a su diagnóstico. Su aparición es de pronóstico desfavorable, pero el diagnóstico precoz y el tratamiento específico pueden mejorar su evolución. Se presenta el caso clínico de un paciente de 15 años con diagnóstico de infección por virus de inmunodeficiencia humana de transmisión vertical, sin tratamiento antirretroviral, con tos y disnea de esfuerzo progresiva asociadas a signos de falla cardíaca derecha en el cual se diagnosticó hipertensión pulmonar grave. Luego de descartarse otras causas, se asumió la hipertensión pulmonar asociada a la infección por virus de inmunodeficiencia humana. Se realizó el tratamiento con sildenafil y presentó buena respuesta. Palabras clave: VIH, hipertensión pulmonar, pediatría, citrato de sildenafil. ABSTRACTPulmonary hypertension associated with human immunodeficiency virus infection is an extremely rare disease in pediatrics; it requires a high clinical suspicion to reach a diagnosis. Its appearance poses an unfavorable prognostic, but early diagnosis and specific treatment can improve outcomes. We report the clinical case of a fifteen-year-old patient diagnosed with human immunodeficiency virus infection of vertical transmission, without antiretroviral treatment, with cough and progressive exertional dyspnea, associated with signs of right heart failure in which severe pulmonary hypertension was diagnosed. After discarding other causes, it was assumed pulmonary hypertension associated with human immunodeficiency virus infection. Treatment was performed with sildenafil with good response.

show abstract

“…32 In low-to-middle income countries, the prevalence among adults is probably much higher, ranging from 8% to 13% in the ART era. 31 In fact, HIV infection presents in one-third of adults with pulmonary arterial hypertension in Africa.…”

Section: Pulmonary Arterial Hypertensionmentioning

confidence: 99%

Cardiovascular manifestations of HIV infection in children

Idris

Grobbee

Burgner

et al. 2014

Eur J Prev Cardiolog

View full text Add to dashboard Cite

HIV infection in children may greatly impact the cardiovascular system, including effects on the heart, which tend to manifest early in childhood, and on the vasculature. The underlying mechanisms, essential for targeted prevention, are poorly understood. Current evidence largely stems from research in adults. However, as modes of infection, immune maturity, growth and development, and treatment are markedly different in children, specific pediatric research, accounting for the complex interplay of normal growth and development, HIV infection and treatment, is clearly warranted.

show abstract

Human Immunodeficiency Virus and Pulmonary Arterial Hypertension

Cited by 11 publications

References 83 publications

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects

Hipertensión pulmonar asociada al virus de la inmunodeficiencia humana en pediatría: tratamiento con sildenafil. A propósito de un caso

Cardiovascular manifestations of HIV infection in children

Contact Info

Product

Resources

About